Zydus Wellness Limited
₹462.25-₹16.90 (-3.5%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹14,052 Cr
- P/E
- 413.0x
- EV / EBITDA
- 275.0x
- Revenue
- ₹293 Cr
- Net margin
- 13.9%
- ROCE
- 0.8%
Price chart
Technical chartScreen technicals →-5.2% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -9.9%
- 3M
- -18.3%
- 6M
- -9.1%
- 1Y
- -5.2%
- 5Y
- +12.5%
52-week range
Day change -₹16.90 (-3.5%) from ₹479 to ₹462 · Last close Oct 30, 2026
Best weekday to invest, historically
The same weekly amount in ZYDUSWELL, bought on each weekday since 2021.
AI Summary
Indian StockStrengths1
- Maintains healthy dividend payout of 94.0%
Concerns1
- Low return on equity of 0.8%
Rule-based from financial data. Not advice.
About the company
Zydus Wellness Limited engages in the development, production, marketing, and distribution of health and wellness products in India, the Middle East, Asia, Africa, the Oceania, and internationally.
Read moreShow less
Zydus Wellness Limited engages in the development, production, marketing, and distribution of health and wellness products in India, the Middle East, Asia, Africa, the Oceania, and internationally. It provides sugar substitute products under the Sugar Free Gold, Sugar Free Natura, and Sugar Free Green brands; milk-based health food drink under the Complan brand; glucose-based beverage under the Glucon-D brand; and I'm lite a blended sugar coated with stevia. The company also offers a range of skincare products, such as soap-free face washes, face masks, scrubs, and leave-on-products under the Everyuth brand; prickly heat and cooling powder, and hand sanitizer under the Nycil brand; and probiotic butter spread, table spread, ghee, butter, cholesterol fat-free spread, mayonnaise, and chocolate spread under the Nutralite brand. It also exports its products. The company was formerly known as Carnation Nutra Analogue Foods Limited and changed its name to Zydus Wellness Limited in January 2009. The company was founded in 1988 and is headquartered in Ahmedabad, India. Zydus Wellness Limited is a subsidiary of Zydus Lifesciences Limited.
- Sector
- Consumer Staples
- Shares outstanding
- 31.8 Cr shares
- ISIN
- INE768C01028
- BSE code
- 531335
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹14,052 Cr
- P/E
- 413.0x
- P/B
- 3.5x
- EV / EBITDA
- 275.0x
- EV / Sales
- 57.3x
- P/S
- 57.4x
- Earnings yield
- 0.2%
- 52-week high
- ₹602.35
- 52-week low
- ₹373.60
Profitability
- Operating margin
- 13.5%
- Net margin
- 13.9%
- EBITDA margin
- 20.8%
- ROE
- 0.8%
- ROCE
- 0.8%
- ROA
- 0.8%
- Dividend payout
- 94.0%
- Tax rate
- 25.0%
- Other income, % of PBT
- 40.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹293 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 19.6%
- Revenue CAGR, 5YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 9.9%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹51.0 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 0.0%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -8.8%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹26.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -29.7%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹7.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 1.2%
Solvency and efficiency
- Current ratio
- 139.93
- Debt / Equity
- 0.01
- Debt / Assets
- 0.01
- Debt / EBITDA
- 1.00
- Interest coverage
- 11.00
- Financial leverage
- 1.02
- CFO / Net profit
- 0.76
- Cash / Market cap
- 2.7%
- Cash per share
- ₹12.02
- Asset turnover
- 0.06
- Fixed asset turnover
- 4.54
- Capital intensity
- 0.22
- Debtor days
- 12 days
- Inventory turnover
- 15.87
- Cash conversion cycle
- -10 days
Where the revenue went
Of every ₹100 of FY2025 revenue, ₹11 was left as net profit.
| From | To | Amount |
|---|---|---|
| Sales | Expenses | ₹256 Cr |
| Sales | Operating profit | ₹37 Cr |
| Operating profit | Interest | ₹4 Cr |
| Operating profit | Depreciation | ₹4 Cr |
| Operating profit | Profit before tax | ₹29 Cr |
| Other income | Profit before tax | ₹12 Cr |
| Profit before tax | Tax and other | ₹10 Cr |
| Profit before tax | Net profit | ₹31 Cr |
Revenue and net profit
Revenue grew 19.6% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹114 Cr | -₹182 Cr |
| FY2022 | ₹216 Cr | ₹13 Cr |
| FY2023 | ₹251 Cr | ₹66 Cr |
| FY2024 | ₹245 Cr | ₹34 Cr |
| FY2025 | ₹293 Cr | ₹31 Cr |
Cash flows
FY2025: ₹46.0 Cr from operations, -₹50.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | -₹52 Cr | ₹764 Cr |
| FY2022 | -₹16 Cr | ₹23 Cr |
| FY2023 | ₹37 Cr | ₹38 Cr |
| FY2024 | ₹26 Cr | -₹21 Cr |
| FY2025 | ₹46 Cr | -₹50 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹293 Cr+19.6%1Y
- Net profit
- ₹31 Cr-8.8%1Y
- Cash from operations
- ₹46 Cr
- Free cash flow
- -₹50 Cr
- Revenue CAGR, 5Y
- 9.9%
- EBITDA CAGR, 5Y
- -10.3%
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹293 Cr | ₹37 Cr | — | ₹31 Cr | ₹46 Cr | -₹50 Cr | 0.8% | +19.6% | -8.8% |
Monthly returns
Month-by-month returns of ZYDUSWELL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹4,214 Cr |
| Equity capital | ₹64 Cr |
| Reserves | ₹3,971 Cr |
| Borrowings | ₹130 Cr |
| Other liabilities | ₹49 Cr |
| Assets | ₹4,214 Cr |
| Fixed assets | ₹57 Cr |
| Capital work in progress | ₹8 Cr |
| Investments | ₹4,061 Cr |
| Other assets | ₹88 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
ZYDUSWELL trades at 413.0x earnings against a peer median of 44.5x (a 828% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Zydus Wellness LimitedZYDUSWELLthis companyP/E ↑ premium | ₹14,052 Cr | 413.0x | 3.5x | 0.8% | 275.0x |
| Hatsun Agro Products Ltd.HATSUN | ₹20,753 Cr | 57.8x | 11.1x | 17.0% | 25.1x |
| E.I.D. Parry (India) Ltd.EIDPARRY | ₹16,781 Cr | 837.0x | 7.4x | 3.7% | 56.9x |
| CCL Products (India) Ltd.CCL | ₹12,958 Cr | 70.8x | 10.2x | 8.5% | 62.2x |
| The Bombay Burmah Trading Corporation Ltd.BBTC | ₹12,667 Cr | 167.0x | 58.2x | -3.1% | 182.8x |
| Cupid LimitedCUPID | ₹11,780 Cr | 191.0x | 30.9x | 13.3% | 202.9x |
| Avanti Feeds ltd.AVANTIFEED | ₹11,080 Cr | 19.3x | 4.3x | 15.5% | 24.6x |
| Godrej Agrovet LimitedGODREJAGRO | ₹10,751 Cr | 18.5x | 4.0x | 15.8% | 17.0x |
| Tilaknagar Industries LtdTI | ₹10,605 Cr | 38.8x | 4.4x | 22.0% | 52.5x |
| Peer median | — | 44.5x | 7.0x | 14.2% | 25.9x |
Year-to-date ROI
ZYDUSWELL since 1 January, against earlier years.
Historical volatility
ZYDUSWELL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | -44.0% |
| FY2022 | -2.0% |
| FY2023 | 15.0% |
| FY2024 | 13.0% |
| FY2025 | 13.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹293 Cr |
| Costs | |
| Interest | ₹4 Cr |
| Expenses | ₹256 Cr |
| Operating profitOperating Profit | ₹37 Cr |
| Other income and charges | |
| Profit before tax | ₹41 Cr |
| Tax | |
| Net profitNet Profit | ₹31 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹4,214 Cr |
| Equity capitalEquity Capital | ₹64 Cr |
| Reserves | ₹3,971 Cr |
| Borrowings | ₹130 Cr |
| Other liabilitiesOther Liabilities | ₹49 Cr |
| AssetsTotal Assets | ₹4,214 Cr |
| Fixed assetsFixed Assets | ₹57 Cr |
| Capital work in progressCWIP | ₹8 Cr |
| Investments | ₹4,061 Cr |
| Other assetsOther Assets | ₹88 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹46 Cr |
| Investing cash flowCash from Investing Activity | -₹96 Cr |
| Financing cash flowCash from Financing Activity | ₹43 Cr |
| Change in cashNet Cash Flow | -₹7 Cr |
Learn while you research
Academy chapters picked for Zydus Wellness Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 413.0, learn when high multiples are justified.6 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Cyclical vs Defensive StocksConsumer staples behave defensively across the business cycle.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read